
Merck & Co agrees to buy biotech firm Afferent for upfront $500 million in cash
pharmafile | June 10, 2016 | News story | Medical Communications, Sales and Marketing | Afferent Pharmaceuticals, Financial, M&A, MA, Merck & Co
US drugmaker Merck & Co (NYSE: MRK) said it has agreed to buy biotech firm Afferent Pharmaceuticals for an upfront payment of $500 million in cash.
The acquisition gives the pharma major access to two drug candidates in mid-stage trials to treat chronic cough utilising P2X3 receptors – believed to help in the sensitization of certain sensory nerves.
In addition, to the upfront amount privately-held Afferent will receive a total of up to an additional $750 million related to achievement of certain milestones.
Roger Perlmutter, president, Merck Research Laboratories, said: “Afferent has pioneered the clinical development of novel investigational candidates selectively targeting the P2X3 receptor, an exciting area of research. We look forward to advancing these innovative molecules for patients with conditions like chronic cough, an area of significant unmet medical need.”
Afferent’s lead drug candidate, AF-219, is currently being studied in a Phase II trials to treat refractory, chronic cough as well as another mid-stage trial for idiopathic pulmonary fibrosis (IPF) with cough.
Anjali Shukla
Related Content

Alchemab Therapeutics signs $415m licensing agreement for ALS programme with Eli Lilly
Alchemab Therapeutics, an immunotherapy-focused biopharma company, has entered a licensing agreement with Eli Lilly and …

Sanofi and CD&R finalise Opella deal, launching global consumer healthcare giant
Sanofi and Clayton, Dubilier & Rice (CD&R) have officially closed the sale of a controlling …

Funding overview for the pharmaceutical industry and outlook for 2020
This article was originally published in the January/February 2020 issue of Pharmafocus.With the advent of …






